Patent · US Active

α4β7 peptide monomer and dimer antagonists

US9809623B2 · kind B2 · utility

24Cited by
15References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 1, 2015
Grant dateNov 7, 2017
Priority date
Expiry dateOct 1, 2035

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.